BETA Stock Overview
Beta Drugs Limited develops, manufactures, and trades in oncology medicines in India.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BETA from our risk checks.
Beta Drugs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,330.25 |
| 52 Week High | ₹1,595.00 |
| 52 Week Low | ₹660.00 |
| Beta | 0.79 |
| 1 Month Change | 6.85% |
| 3 Month Change | -5.25% |
| 1 Year Change | 75.03% |
| 3 Year Change | 620.81% |
| 5 Year Change | 1,028.29% |
| Change since IPO | 1,156.14% |
Recent News & Updates
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11Recent updates
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Shareholder Returns
| BETA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.8% | -1.4% | -1.6% |
| 1Y | 75.0% | 53.7% | 45.0% |
Return vs Industry: BETA exceeded the Indian Pharmaceuticals industry which returned 53.7% over the past year.
Return vs Market: BETA exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| BETA volatility | |
|---|---|
| BETA Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: BETA has not had significant price volatility in the past 3 months.
Volatility Over Time: BETA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 315 | Rahul Batra | betadrugslimited.com |
Beta Drugs Limited develops, manufactures, and trades in oncology medicines in India. The company offers oncology products, including injections, tablets, and capsules in the areas of breast, lung, head and neck, colorectal, ovarian, gastric, testicular, renal, and prostate cancer, as well as brain tumor, leukemia, lymphoma, myeloma, and supportive cancer. It also provides active pharmaceutical ingredients and pharmaceutical formulation intermediates.
Beta Drugs Limited Fundamentals Summary
| BETA fundamental statistics | |
|---|---|
| Market cap | ₹13.33b |
| Earnings (TTM) | ₹347.57m |
| Revenue (TTM) | ₹2.56b |
36.8x
P/E Ratio5.0x
P/S RatioIs BETA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BETA income statement (TTM) | |
|---|---|
| Revenue | ₹2.56b |
| Cost of Revenue | ₹1.49b |
| Gross Profit | ₹1.07b |
| Other Expenses | ₹721.52m |
| Earnings | ₹347.57m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 36.15 |
| Gross Margin | 41.76% |
| Net Profit Margin | 13.58% |
| Debt/Equity Ratio | 10.9% |
How did BETA perform over the long term?
See historical performance and comparison